Skip to content

Belinostat

Histone Deacetylase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: beleodaq, PXD101

OnpFDA approvedATC L01XH04

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Belinostat is an onp drug in the Histone Deacetylase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2014. Its mechanism of action is classified as Histone Deacetylase Inhibitors. DrugCentral lists 15 molecular targets, including HDAC2, HDAC1 and HDAC3. Recorded indications include Peripheral T-cell lymphoma.

  • Approval status: onp (first approved 2014 by the FDA).
  • Drug class: Histone Deacetylase Inhibitor.
  • Mechanism of action: Histone Deacetylase Inhibitors.
  • Molecular targets: HDAC2, HDAC1, HDAC3 and HDAC6 (15 listed in DrugCentral).
  • Indications: Peripheral T-cell lymphoma.
  • ATC code: L01XH04 (Histone deacetylase (HDAC) inhibitors).
  • Molecular formula: C15H14N2O4S; molecular weight 318.35 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Peripheral T-cell lymphoma

Mechanism & targets

Mechanism of action (MoA)Histone Deacetylase Inhibitors
Established pharmacologic classHistone Deacetylase Inhibitor

Molecular targets (15)

TargetGeneActionActivity
Histone deacetylase 2HDAC2inhibitorKi 9.07
Histone deacetylase 1HDAC1inhibitorKi 9.07
Histone deacetylase 3HDAC3inhibitorKi 8.82
Histone deacetylase 6HDAC6inhibitorKi 8.80
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformPIK3CAunknownIC50 8.54
Histone deacetylase 8HDAC8inhibitorKi 7.66
Histone deacetylase 9HDAC9inhibitorKi 7.62
Histone deacetylase 5HDAC5inhibitorKi 7.60
Bromodomain-containing protein 4BRD4unknownIC50 7.57
Histone deacetylase 11HDAC11inhibitorKi 7.57
Histone deacetylase 4HDAC4inhibitorIC50 7.57
Histone deacetylase 7HDAC7inhibitorKi 7.29
Histone deacetylase 10HDAC10inhibitorKi 7.23
Histone deacetylaseHDAC1unknownIC50 6.67
Aspartyl/asparaginyl beta-hydroxylaseASPHunknownIC50 5.51

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2014-07-03FDA—SPECTRUM PHARMS

ATC classification

ATC codeTherapeutic hierarchy
L01XH04ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Histone deacetylase (HDAC) inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • EMA label
  • FDA label: UGT1A1 · Actionable PGx
  • HCSC label

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Disease progression146.5
Neutrophil count decreased43.6
Platelet count decreased43.4
Anaemia42.6

Chemical structure

Molecular formulaC15H14N2O4S
Molecular weight318.35 g/mol
CAS number414864-00-9
InChIKeyNCNRHFGMJRPRSK-UHFFFAOYSA-N
PubChem CID6918638
ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Belinostat used for?

DrugCentral lists the following indications for Belinostat: Peripheral T-cell lymphoma.

How does Belinostat work?

Belinostat is classified as Histone Deacetylase Inhibitors; its molecular targets in DrugCentral include HDAC2 (inhibitor), HDAC1 (inhibitor), HDAC3 (inhibitor) and HDAC6 (inhibitor).

When was Belinostat first approved?

Belinostat was first approved by the FDA in 2014.

What drug class does Belinostat belong to?

Belinostat is in the Histone Deacetylase Inhibitor class.

What is the chemical formula of Belinostat?

Belinostat has the molecular formula C15H14N2O4S and a molecular weight of 318.35 g/mol.

Browse: all drugs starting with B · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2014-07-03
AgencyFDA
Targets15
Indications1
FormulaC15H14N2O4S
DrugCentral ID4876
Interactive profile